A preventive immunization approach against insect bite hypersensitivity: Intralymphatic injection with recombinant allergens in Alum or Alum and monophosphoryl lipid A

详细信息    查看全文

• 作者：Sigridur Jonsdottir^a ; ^{sij9@hi.is" class="auth_mail" title="E-mail the corresponding author} ; Vilhjalmur Svansson^a ; Sara Bjork Stefansdottir^a ; Gertraud Schü ; pbach^b ; Claudio Rhyner^c ; Eliane Marti^b ; ¹ ; Sigurbjorg Torsteinsdottir^a ; ¹
• 关键词：Horses ; Insect bite hypersensitivity ; Immunotherapy ; Adjuvants ; IgG subclasses
• 刊名：Veterinary Immunology and Immunopathology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：172
• 期：Complete
• 页码：14-20
• 全文大小：1104 K

文摘

Insect bite hypersensitivity (IBH) is an IgE-mediated dermatitis of horses caused by bites of Culicoides insects, not indigenous to Iceland. Horses born in Iceland and exported to Culicoides-rich areas are frequently affected with IBH.

The aims of the study were to compare immunization with recombinant allergens using the adjuvant aluminum hydroxide (Alum) alone or combined with monophosphoryl lipid A (MPLA) for development of a preventive immunization against IBH.

Twelve healthy Icelandic horses were vaccinated intralymphatically three times with 10 μg each of four recombinant Culicoides nubeculosus allergens in Alum or in Alum/MPLA.

Injection with allergens in both Alum and Alum/MPLA resulted in significant increase in specific IgG subclasses and IgA against all r-allergens with no significant differences between the adjuvant groups. The induced antibodies from both groups could block binding of allergen specific IgE from IBH affected horses to a similar extent. No IgE-mediated reactions were induced. Allergen-stimulated PBMC from Alum/MPLA horses but not from Alum only horses produced significantly more IFNγ and IL-10 than PBMC from non-vaccinated control horses.

In conclusion, intralymphatic administration of small amounts of pure allergens in Alum/MPLA induces high IgG antibody levels and Th1/Treg immune response and is a promising approach for immunoprophylaxis and immunotherapy against IBH.